Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy.

Cidado J, Park BH.

J Mammary Gland Biol Neoplasia. 2012 Dec;17(3-4):205-16. doi: 10.1007/s10911-012-9264-2. Epub 2012 Aug 4. Review.

2.

Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling.

Grunt TW, Mariani GL.

Curr Cancer Drug Targets. 2013 Feb;13(2):188-204. Review.

PMID:
23215720
3.

Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients.

Ghayad SE, Cohen PA.

Recent Pat Anticancer Drug Discov. 2010 Jan;5(1):29-57. Review.

PMID:
19751211
4.

PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?

Abraham J.

Expert Rev Anticancer Ther. 2015 Jan;15(1):51-68. doi: 10.1586/14737140.2015.961429. Epub 2014 Oct 11. Review.

PMID:
25306975
5.

Targeting the PI3-kinase/Akt/mTOR signaling pathway.

Hassan B, Akcakanat A, Holder AM, Meric-Bernstam F.

Surg Oncol Clin N Am. 2013 Oct;22(4):641-64. doi: 10.1016/j.soc.2013.06.008. Epub 2013 Aug 6. Review.

6.

The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer.

Lauring J, Park BH, Wolff AC.

J Natl Compr Canc Netw. 2013 Jun 1;11(6):670-8. Review.

7.

Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.

Barrett D, Brown VI, Grupp SA, Teachey DT.

Paediatr Drugs. 2012 Oct 1;14(5):299-316. doi: 10.2165/11594740-000000000-00000. Review.

8.
9.

The PI3K/AKT Pathway as a Target for Cancer Treatment.

Mayer IA, Arteaga CL.

Annu Rev Med. 2016;67:11-28. doi: 10.1146/annurev-med-062913-051343. Epub 2015 Oct 14. Review.

PMID:
26473415
10.

PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy.

Manfredi GI, Dicitore A, Gaudenzi G, Caraglia M, Persani L, Vitale G.

Endocrine. 2015 Mar;48(2):363-70. doi: 10.1007/s12020-014-0380-1. Epub 2014 Aug 13. Review. Erratum in: Endocrine. 2016 Sep;53(3):874.

PMID:
25115638
11.

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.

Polivka J Jr, Janku F.

Pharmacol Ther. 2014 May;142(2):164-75. doi: 10.1016/j.pharmthera.2013.12.004. Epub 2013 Dec 9. Review.

PMID:
24333502
12.

The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.

Mabuchi S, Kuroda H, Takahashi R, Sasano T.

Gynecol Oncol. 2015 Apr;137(1):173-9. doi: 10.1016/j.ygyno.2015.02.003. Epub 2015 Feb 10. Review.

PMID:
25677064
13.

Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.

O'Brien NA, McDonald K, Tong L, von Euw E, Kalous O, Conklin D, Hurvitz SA, di Tomaso E, Schnell C, Linnartz R, Finn RS, Hirawat S, Slamon DJ.

Clin Cancer Res. 2014 Jul 1;20(13):3507-20. doi: 10.1158/1078-0432.CCR-13-2769. Epub 2014 May 30.

14.
15.

Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.

Ciruelos Gil EM.

Cancer Treat Rev. 2014 Aug;40(7):862-71. doi: 10.1016/j.ctrv.2014.03.004. Epub 2014 Mar 26. Review.

PMID:
24774538
16.

Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer.

Hernandez-Aya LF, Gonzalez-Angulo AM.

Oncologist. 2011;16(4):404-14. doi: 10.1634/theoncologist.2010-0402. Epub 2011 Mar 15. Review.

17.

Targeting PI3K/AKT/mTOR network for treatment of leukemia.

Bertacchini J, Heidari N, Mediani L, Capitani S, Shahjahani M, Ahmadzadeh A, Saki N.

Cell Mol Life Sci. 2015 Jun;72(12):2337-47. doi: 10.1007/s00018-015-1867-5. Epub 2015 Feb 25. Review.

PMID:
25712020
18.

Recent development in targeting PI3K-Akt-mTOR signaling for anticancer therapeutic strategies.

Qazi AK, Hussain A, Hamid A, Qurishi Y, Majeed R, Ahmad M, Najar RA, Bhat JA, Singh SK, Zargar MA, Ali S, Saxena AK.

Anticancer Agents Med Chem. 2013 Dec;13(10):1552-64. Review.

PMID:
23438828
19.

Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance.

Chang L, Graham PH, Ni J, Hao J, Bucci J, Cozzi PJ, Li Y.

Crit Rev Oncol Hematol. 2015 Dec;96(3):507-17. doi: 10.1016/j.critrevonc.2015.07.005. Epub 2015 Jul 18. Review.

PMID:
26253360
20.

Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.

Zhou Q, Lui VW, Yeo W.

Future Oncol. 2011 Oct;7(10):1149-67. doi: 10.2217/fon.11.95. Review. Erratum in: Future Oncol. 2012 Jan;8(1):112.

PMID:
21992728

Supplemental Content

Support Center